Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
מצבים רפואיים
Gastric or Gastroesophageal Junction Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancer (BTC)
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
University of Iowa, Iowa City, Iowa, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
Duke Cancer Center, Durham, North Carolina, United States
University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center, GI Medical Oncology Dept, Houston, Texas, United States
NEXT Oncology, Fairfax, Virginia, United States
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States